Targeting Prohibitins to Inhibit Melanoma Growth and Overcome Resistance to Targeted Therapies

Despite important advances in the treatment of metastatic melanoma with the development of MAPK-targeted agents and immune checkpoint inhibitors, the majority of patients either do not respond to therapies or develop acquired resistance. Furthermore, there is no effective targeted therapy currently...

Full description

Bibliographic Details

Published in:	Cells
Main Authors:	Ahmad Najem, Mohammad Krayem, Serena Sabbah, Matilde Pesetti, Fabrice Journe, Ahmad Awada, Laurent Désaubry, Ghanem E. Ghanem
Format:	Article
Language:	English
Published:	MDPI AG 2023-07-01
Subjects:	melanoma prohibitins mitochondria-targeted agents (MTA) drug resistance MAPKi therapeutic strategy
Online Access:	https://www.mdpi.com/2073-4409/12/14/1855